Puma Biotechnology | PBYI - Trade Creditors


Puma Biotechnology reported $6.39M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Agios Pharmaceuticals USD 16.34M 2.6M Jun/2026
Alnylam Pharmaceuticals USD 108.02M 18.61M Jun/2026
Amgen USD 2.86B 16.65B Jun/2026
Biogen USD 403.9M 45.4M Jun/2026
BioMarin Pharmaceutical USD 913.67M 120.52M Jun/2026
Daiichi Sankyo JPY 539.05B 57.81B Jun/2026
Exelixis USD 39.06M 14.91M Jun/2026
Gilead Sciences USD 645M 70M Mar/2026
Glaxosmithkline GBP 14.34B 6.39B Mar/2026
Incyte USD 1.39B 1.16B Jun/2026
MacroGenics USD 3.44M 845K Jun/2026
Moderna USD 167M 6M Jun/2026
Novartis USD 4.26B 64M Jun/2026
Pfizer USD 4.58B 75M Jun/2026
PTC Therapeutics USD 40.45M 14.96M Jun/2026
Puma Biotechnology USD 6.39M 962K Sep/2025
Regeneron Pharmaceuticals USD 1.16B 132.2M Jun/2026
Roche Holding CHF 5.54B 237M Jun/2026
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sarepta Therapeutics USD 50.98M 19.39M Jun/2026
Takeda JPY 446.78B 44.56B Jun/2026
TG Therapeutics USD 213.69M 64.85M Jun/2026
Ultragenyx Pharmaceutical USD 39M 3M Jun/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024
Vertex Pharmaceuticals USD 3.61B 135M Jun/2026